Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

World Journal of Gastroenterology

Volumn 19, Issue 21, 2013, Pages 3199-3206

  Zeng, Qing Lei ^a   Zhang, Ji Yuan ^b   Zhang, Zheng ^b   Wang, Li Feng ^b   Wang, Fu Sheng ^a  

^a PEKING UNIVERSITY   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

ABT 450; Antiviral therapy; Hepatitis C virus; Sofosbuvir; Sustained virologic response

Indexed keywords

ABT 333; ABT 450; ALISPORIVIR; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; INTERLEUKIN 28B; MERICITABINE; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA;

ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEVER; GENETIC ASSOCIATION; GENOTYPE; HEADACHE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; MONOTHERAPY; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VOMITING;

EID: 84878645472     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i21.3199     Document Type: Article

References (52)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567. [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115. [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
4. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593. [PMID: 19625712 DOI: 10.1056/NEJMoa0808010]
5. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652. [PMID: 12939591 DOI: 10.1053/jhep.2003.50364]
6. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103. [PMID: 16290907 DOI: 10.1016/j.jhep.2005.10.003]
7. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of sideeffects. Liver Int 2013; 33 Suppl 1: 30-34. [PMID: 23286843 DOI: 10.1111/liv.12080]
8. Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection. Liver Int 2013; 33 Suppl 1: 14-22. [PMID: 23286841 DOI: 10.1111/liv.12070]
9. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578. [PMID: 3097544 DOI: 10.1056/ NEJM198612183152503]
10. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510. [PMID: 2509917 DOI: 10.1056/NEJM198911303212204]
11. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506. [PMID: 2509916 DOI: 10.1056/ NEJM198911303212203]
12. Thomson BJ, Doran M, Lever AM, Webster AD. Alphainterferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987; 1: 539-541. [PMID: 2434816]
13. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397. [PMID: 1900254]
14. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492. [PMID: 9819446 DOI: 10.1056/NEJM199811193392101]
15. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499. [PMID: 9819447 DOI: 10.1056/NEJM199811193392102]
16. Liang TJ. Combination therapy for hepatitis C infection. N Engl J Med 1998; 339: 1549-1550. [PMID: 9819457 DOI: 10.1056/NEJM199811193392112]
17. Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995; 27: 325-329. [PMID: 8658064]
18. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 Suppl 2: 8-12. [PMID: 8720287]
19. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996; 28: 505-511. [PMID: 9131395]
20. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Idéo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997; 4: 185-191. [PMID: 9181527]
21. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26: 108S-111S. [PMID: 9305674 DOI: 10.1002/hep.510260719]
22. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebocontrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87. [PMID: 9439491]
23. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680. [PMID: 11106716 DOI: 10.1056/ NEJM200012073432302]
24. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672. [PMID: 11106715 DOI: 10.1056/NEJM200012073432301]
25. Schafer DF, Sorrell MF. Conquering hepatitis C, step by step. N Engl J Med 2000; 343: 1723-1724. [PMID: 11106723 DOI: 10.1056/NEJM200012073432309]
26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982. [PMID: 12324553 DOI: 10.1056/ NEJMoa020047]
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. [PMID: 11583749]
28. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601. [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]
29. Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL. Experimental models for hepatitis C viral infection. Hepatology 2009; 50: 1646-1655. [PMID: 19670425 DOI: 10.1002/ hep.23138]
30. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416. [PMID: 21696307 DOI: 10.1056/ NEJMoa1012912]
31. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024. [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]
32. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428. [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
33. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217. [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
34. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206. [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
35. Pan Q, Peppelenbosch MP, Janssen HL, de Knegt RJ. Telaprevir/ boceprevir era: from bench to bed and back. World J Gastroenterol 2012; 18: 6183-6188. [PMID: 23180937 DOI: 10.3748/wjg.v18.i43.6183]
36. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224. [PMID: 22256805 DOI: 10.1056/NEJMoa1104430]
37. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44. [PMID: 23281974 DOI: 10.1056/ NEJMoa1208953]
38. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53. [PMID: 23281975 DOI: 10.1056/NEJMoa1208809]
39. Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol 2011; 35 Suppl 2: S84-S95. [PMID: 22248700 DOI: 10.1016/ S2210-7401(11)70013-4]
40. Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009; 23: 2237-2245. [PMID: 19809270 DOI: 10.1097/ QAD.0b013e328332c3a5]
41. Pilot-Matias T, Tripathi R, Dekhtyar T, Menon R, Gaultier I, Cohen D, Podsadecki T, Bernstein B, Collins C. Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450. J Hepatol 2011; 54 Suppl 1: S485-S486 [DOI: 10.1016/S0168-8278(11)61231-2]
42. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 2012 Nov 23; Epub ahead of print. [PMID: 23183528 DOI: 10.1016/ j.jhep.2012.11.018]
43. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401. [PMID: 19684573 DOI: 10.1038/nature08309]
44. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109. [PMID: 19749757 DOI: 10.1038/ng.449]
45. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104. [PMID: 19749758 DOI: 10.1038/ng.447]
46. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345. e1-7. [PMID: 20060832 DOI: 10.1053/j.gastro.2009.12.056]
47. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28: 38-45. [PMID: 23137126 DOI: 10.1111/jgh.12028]
48. Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 2013 Jan 15; Epub ahead of print. [PMID: 23322441 DOI: 10.1136/gutjnl-2012-302600]
49. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-758. [PMID: 22006408 DOI: 10.1002/hep.24744]
50. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604-1612. [PMID: 18285474 DOI: 10.1128/AAC.01317-07]
51. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275. [PMID: 22256811 DOI: 10.1056/NEJMe1113272]
52. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011; 364: 1272-1274. [PMID: 21449791 DOI: 10.1056/ NEJMe1100829]